First patient dosed with engineered B Cell therapy

“Immusoft [Seattle, WA] has dosed the first patient with an engineered B cell therapy—ISP-001 for MPS I (Mucopolysaccharidosis type I). This approach has several potential advantages over current gene and cell therapies. It does not require preconditioning (myeloablative chemotherapy) or immunosuppression, is administered as an IV on an outpatient basis, and it appears engineered B cells can be given repeatedly without causing resistance to develop.”   MORE

Image Credit:  InsidePrecisionMedicine